Haemonetics Corporation
NYSEHAE upgraded to Buy by Citigroup with $123 price target, up 34% from prior $92, implying 16% upside to current $106 close. Analyst Joanne Wuensch cites strong fundamentals in blood management and medical technology segments.
Haemonetics heads into the week having done something rare — it left the analyst consensus behind. The stock closed at $104.65 on August 18, up 20% on the week and 34% over the past month. The move was triggered by an…
Haemonetics delivered a clean earnings beat on August 6 and the Street responded fast — target prices moved sharply higher across the board, with the stock now sitting at $87.84 and up 17% over the past month. The…
Snapshot as of 4 Oct 2026
HAE heads into its August 6 earnings report with the options market sending a clear bullish signal — one that the stock's sharp recent rally has done nothing to contradict. The most striking positioning data is in…
Haemonetics heads into the summer with a split personality: the analyst community is upgrading its view just as short sellers add to their bets — a tension the stock's recent price action has not yet resolved. The…
Haemonetics Corporation enters its May 7 earnings call in an unusual spot: short sellers have been cutting exposure for six weeks, options traders are positioned bullishly, and yet the stock trades at a near-50%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HAE — free to start on ORTEX.
Sign up for free →Open HAE on ORTEX